Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases.
Excellent balance sheet with questionable track record.
Share Price & News
How has Enanta Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
1 Year Return
Return vs Industry: ENTA underperformed the US Biotechs industry which returned -5.5% over the past year.
Return vs Market: ENTA underperformed the US Market which returned 8% over the past year.
Price Volatility Vs. Market
How volatile is Enanta Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StIs Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) High P/E Ratio A Problem For Investors?
3 weeks ago | Simply Wall StShould You Be Worried About Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) 14% Return On Equity?
1 month ago | Simply Wall StDoes The Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Share Price Tend To Follow The Market?
Is Enanta Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ENTA ($60.97) is trading above our estimate of fair value ($12.86)
Significantly Below Fair Value: ENTA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ENTA is poor value based on its PE Ratio (18.4x) compared to the Biotechs industry average (16.4x).
PE vs Market: ENTA is poor value based on its PE Ratio (18.4x) compared to the US market (17.6x).
Price to Earnings Growth Ratio
PEG Ratio: ENTA's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: ENTA is overvalued based on its PB Ratio (2.7x) compared to the US Biotechs industry average (2.6x).
How is Enanta Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ENTA's earnings are forecast to decline over the next 3 years (-7.3% per year).
Earnings vs Market: ENTA's earnings are forecast to decline over the next 3 years (-7.3% per year).
High Growth Earnings: ENTA's earnings are forecast to decline over the next 3 years.
Revenue vs Market: ENTA's revenue (5.4% per year) is forecast to grow slower than the US market (7.2% per year).
High Growth Revenue: ENTA's revenue (5.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ENTA is forecast to be unprofitable in 3 years.
How has Enanta Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: ENTA's earnings have grown by 0.6% per year over the past 5 years.
Accelerating Growth: ENTA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ENTA had negative earnings growth (-20.3%) over the past year, making it difficult to compare to the Biotechs industry average (83.4%).
Return on Equity
High ROE: ENTA's Return on Equity (14.4%) is considered low.
Return on Assets
ROA vs Industry: ENTA's Return on Assets is below or equal to the Biotechs industry average last year.
Return on Capital Employed
ROCE Improving: ENTA has improved its Return on Capital Employed over the past 3 years.
How is Enanta Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ENTA's short term assets ($451.3M) exceeds its short term liabilities ($20.5M)
Long Term Liabilities: ENTA's short term assets (451.3M) exceeds its long term liabilities (4.9M)
Debt to Equity History and Analysis
Debt Level: ENTA's debt to equity ratio (0.4%) is considered satisfactory
Reducing Debt: ENTA's debt to equity ratio has increased from 0.1% to 0.4% over the past 5 years.
Debt Coverage: ENTA's debt is well covered by operating cash flow (5602.8%).
Interest Coverage: ENTA earns more interest than it pays, so coverage of interest payments is not a concern.
Inventory Level: ENTA has a low level of unsold assets or inventory.
Debt Coverage by Assets: ENTA's debt is covered by short term assets (assets are 277.187960x debt).
What is Enanta Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate ENTA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ENTA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if ENTA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ENTA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ENTA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
What is the CEO of Enanta Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
Jay Luly (63yo)
Dr. Jay R. Luly, Ph.D. has been the Chief Executive Officer and President of Enanta Pharmaceuticals, Inc. since July 2003. Dr. Luly joined Enanta in July 2003. Previously he was employed at Oxford Bioscien ...
CEO Compensation Analysis
Compensation vs. Market: Jay's total compensation ($USD4.51M) is about average for companies of similar size in the US market ($USD2.67M).
Compensation vs Earnings: Jay's compensation has been consistent with company performance over the past year.
Management Age and Tenure
Experienced Management: ENTA's management team is seasoned and experienced (16.1 years average tenure).
Board Age and Tenure
Experienced Board: ENTA's board of directors are considered experienced (4.8 years average tenure).
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Paul Mellett (64yo)
Senior VP of Finance & Administration and CFO
- Tenure: 16.1yrs
- Compensation: US$1.42m
Jay Luly (63yo)
- Tenure: 16.3yrs
- Compensation: US$4.51m
Yat Or (67yo)
Senior VP of Research & Development and Chief Scientific Officer
- Tenure: 19.9yrs
- Compensation: US$1.52m
Nathaniel Gardiner (65yo)
- Tenure: 5.4yrs
- Compensation: US$1.38m
Nathalie Adda (53yo)
Senior VP & Chief Medical Officer
- Tenure: 4.3yrs
- Compensation: US$1.51m
Director of Investor Relations
- Tenure: 0yrs
Bruce L. Carter (76yo)
- Tenure: 3.8yrs
- Compensation: US$394.19k
Jay Luly (63yo)
- Tenure: 16.3yrs
- Compensation: US$4.51m
Terry Vance (61yo)
- Tenure: 8.3yrs
- Compensation: US$374.19k
Kris Peterson (60yo)
- Tenure: 2.1yrs
- Compensation: US$205.85k
George Golumbeski (62yo)
- Tenure: 5.7yrs
- Compensation: US$366.69k
Lesley Russell (58yo)
- Tenure: 2.9yrs
- Compensation: US$361.69k
Enanta Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Enanta Pharmaceuticals, Inc.
- Ticker: ENTA
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.200b
- Shares outstanding: 19.68m
- Website: https://www.enanta.com
Number of Employees
- Enanta Pharmaceuticals, Inc.
- 500 Arsenal Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ENTA||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Mar 2013|
|9EP||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Mar 2013|
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/22 00:23|
|End of Day Share Price||2019/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.